










# Access and Global Health



At VIATRIS™, we believe that access is incredibly personal. It is fundamental to our mission and a universal need and right, especially important in challenging times. Given Viatris’ unique portfolio and footprint, we have the opportunity to touch all of life’s moments, from birth to end of life, acute conditions and chronic diseases. We see across multiple therapeutic areas to the person at the center of their own unique health journey.

Viatriis was formed to bridge the traditional divide between generics and brands, combining the best of both, to more holistically address healthcare needs globally. We are focused on meeting individual needs, whether with a generic medicine, an improved version of an existing medicine, or a truly novel therapeutic solution.

 <p>Supplying high-quality medicines to <b>~1B patients around the world</b> annually*</p>	 <p>Sold more than <b>80 billion</b> doses of medicine across more than <b>165 countries and territories</b>, reaching about <b>90% of low- and lower middle-income countries</b></p>	 <p><b>&gt;250 medicines on the WHO Essential Medicines List</b> to help address priority healthcare needs as defined by the WHO</p>	 <p><b>62 products on the WHO Prequalification List</b>, which allows for U.N. and other multilateral donor procurement, as well as accelerated registration processes in low- and lower middle- income countries</p>
 <p>Received <b>&gt;470 global product approvals</b></p>	 <p>Locally available medicines addressed <b>at least half of the top ten local causes of death, across all country income bands, in &gt;100 countries</b></p>	 <p>Completed <b>&gt;134 submissions in &gt;110 different countries, including &gt;85 products</b> in Emerging Markets</p>	 <p>Made <b>&gt;600 regulatory filings, which includes &gt;250 individual market submissions</b> for Emerging Markets</p>

## Advancing On Our Initial Access Goals

We go beyond developing, making, and distributing high-quality medicines. With the needs of people at the heart of what we do, we work to help find solutions that support resilient health systems. We have designed our global operations and supply chain to be a reliable and flexible partner for access across the world, constantly adapting to an ever-evolving landscape.

We pursue holistic approaches to prevention, diagnosis, treatment, and disease management. We work to build public health awareness, to support and implement research, to deliver access to health education, and to advocate for public policies that advance sustainable access. As a global healthcare company committed to truly supporting equity in access to treatment, we advocate for policies that help modernize competition, advancing and protecting access across a web of interrelated policies to build systems that sustain access.

### Our Access Goals:



- ▶ Provide antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.

**Our Progress:** In 2022, we made progress toward our goal by providing treatments for approximately 8 million patients, including almost 600,000 children living with HIV/AIDS.

- ▶ Impact 100 million patients via healthcare professional (HCP) education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

**Our Progress:** More than 19,000 individuals have an NCD Academy account, representing approximately 48.6 million patients impacted.<sup>2</sup>

# Advancing Progress for Infectious Disease Prevention, Diagnosis and Treatment

As a leading global supplier of ARVs used to prevent and treat HIV, we have a strong legacy of supporting people living with HIV. In 2022, we provided access to high-quality and affordable ARVs to more than 100 countries. More than 30% of adults and more than 65% of children being treated for HIV in our Emerging Markets segment in 2022 used a Viatriis product.<sup>3</sup>

We are also uniquely engaged in partnerships to address tuberculosis (TB), including through our efforts to bring new treatments addressing drug-resistant TB more equitably to patients around the world. Viatriis has launched pretomanid, specifically approved for adults with MDR-TB. It's only the third new anti-TB drug approved in the past half-century.

## Reducing the Burden of NCDs

Noncommunicable diseases (NCDs) cause approximately 41 million deaths each year globally and encompass a range of conditions including hypertension, diabetes, cancer, mental health conditions and cardiovascular disease.

Viatriis' broad portfolio helps address these areas and, via our commercial footprint and partnerships, we seek to leverage our portfolio to bring access to medicines and supporting services to patients and healthcare systems across the world.

## Seeking Meaningful Policies for Access

Our Viatriis colleagues work to identify access barriers unique to places and health systems around the world so we can identify policies to create long-lasting change, share our knowledge and experience broadly, and help ensure progress is made.

Shared barriers to sustainable access need shared solutions, which is why we seek to align our global policy strategy to maximize our impact. In 2022, Viatriis' global policy priorities focused on championing policies advancing efficiency of regulatory systems, creating pro-competitive policy environments, and supporting long-term market viability and global supply networks to tackle the root causes of supply disruption.

## Global and Diverse Manufacturing and Supply Chain Capabilities

Global, diverse and flexible supply chains are key to timely and affordable access to medicine. Viatriis operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs on five different continents.<sup>4</sup> Our global, flexible, and diverse supply chain is designed to mitigate risks of disruption and ensure supply reliability. Our responsive global network has helped us maintain a reliable supply of much-needed medicines throughout times of significant demand volatility.

## Helping Curb Antimicrobial Resistance

As one of the world's largest suppliers of antimicrobials, including antibiotics and antiretrovirals, Viatriis is uniquely committed to addressing antimicrobial resistance (AMR). As a founding member of the AMR Industry Alliance, Viatriis has long believed in the power of cross-sectoral partnership to achieve greater results, together. AMR is a complex problem, and in many ways highlights broader issues impacting medicines and healthcare access more broadly.

In 2022, Viatriis through the AMRIA contributed to work identifying root causes of and potential solutions for constraints in the off-patent antibiotic supply chain. We also participated in thought leadership to advance awareness of the challenge posed to modern healthcare by AMR, and how stakeholders including policymakers, healthcare providers and patients can contribute to tackling the problem, together.

We collaborated in the launch of the first environmental manufacturing standard for antibiotics. All applicable Viatriis manufacturing locations with antibiotic production have been assessed and adhere to the AMRIA Antibiotic Manufacturing Standard.

<sup>1</sup> The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2022 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatriis Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatriis medicines may be counted as multiple patients. Certain adjustments were applied in consideration of announced divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

<sup>2</sup> Patient reach calculated by multiplying the number of HCP learners by the average number of patients treated, as self-reported by HCP learners upon registering for NCD Academy. Patient reach includes unique patients as well as repeat patient encounters. As of January 2023.

<sup>3</sup> Excludes the U.S., EU and other developed markets. Also excludes Russia, China and Mexico, where we do not commercialize ARVs.

<sup>4</sup> Not taking into account the planned divestitures of certain API manufacturing and manufacturing of certain women's health products in India, which are yet to be completed.



Viatriis.com



LinkedIn



@ViatriisInc



@ViatriisInc



YouTube



Listen Well Podcast